Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 15/20 | 1.00 |
| ▸ | AXL | P30530 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | FLT4 | P35916 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471101 | 1.00 | KDR (1.00) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL29365812 | 1.00 | KDR (1.00) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4478619 | 1.00 | KDR (1.00) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL29391280 | 1.00 | KDR (1.00) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4473907 | 0.92 | KDR (0.86) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4483651 | 0.92 | KDR (0.86) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4486627 | 0.92 | KDR (0.86) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4491837 | 0.90 | KDR (0.82) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4471525 | 0.90 | KDR (0.82) | KDRPDGFRAAXLKITPDGFRB | |
| SCHEMBL4483959 | 0.90 | KDR (0.82) | KDRPDGFRAAXLKITPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | claimed |
| CN-111068054-A | Medicament for treating tumor by using CSF1R as drug target and preparation method thereof | 浙江大学医学院附属第一医院 | 2020-04-28 | — | — | CN | claimed |
| US-20190142722-A1 | METHODS AND COMPOSITIONS FOR PROMOTING OR INDUCING HAIR GROWTH | UNIV COLUMBIA (US) | 2019-05-16 | — | — | US | claimed |
| WO-2013120896-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF A NEUROGENERATIVE DISEASE OR A DISEASE INVOLVING AN ACTIVATION OF PHOSPHODIESTERASE-4 (PDE4) | HARMONIC PHARMA (FR) | 2013-08-22 | — | — | WO | claimed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | claimed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | claimed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | claimed |
| US-11740231-B2 | Articles of manufacture and methods related to toxicity associated with cell therapy | JUNO THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230172988-A1 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172988-A1 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230149458-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230053787-A1 | METHODS RELATED TO TOXICITY AND RESPONSE ASSOCIATED WITH CELL THERAPY FOR TREATING B CELL MALIGNANCIES | JUNO THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2017176792-A1 | METHODS OF PREVENTING OR REDUCING A FIBROTIC RESPONSE USING CSF 1R INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2013120896-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF A NEUROGENERATIVE DISEASE OR A DISEASE INVOLVING AN ACTIVATION OF PHOSPHODIESTERASE-4 (PDE4) | HARMONIC PHARMA (FR) | 2013-08-22 | — | — | WO | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11740231-B2 | Articles of manufacture and methods related to toxicity associated with cell therapy | TNF, IL2, PBK | KDR 2017/4885PDGFRA 979/4885AXL 976/4885 |
| US-20230149458-A1 | ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | ICOS, PBK, BCL6 | KDR 443/4885PDGFRA 711/4885AXL 682/4885 |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | CSF3R, CSF1R, MSR1 | KDR 122/4885PDGFRA 137/4885AXL 164/4885 |
| US-20230172988-A1 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | IL2, TSLP, TNF | KDR 1995/4885PDGFRA 733/4885AXL 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.